Question

42-year-old female, with diffuse cutaneous systemic sclerosis, presents with SOB/cough. CXR shows ILD. FVC 50% predicted, DLCO 30% predicted. ECG and imaging shows right ventricular enlargement and dilated PA s/o pulmonary hypertension. Most appropriate next step in management is?

• A. Start systemic steroids
• B. Start CYC 500mg IV every 2 weeks
• C. Refer to lung transplant evaluation
• D. Start endothelin receptor antagonist(bosentan)

Hint:

While systemic steroids are often the correct board answer for acute ILD flares in conditions like Dermatomyositis or SLE, be extremely cautious with them in Systemic Sclerosis in real clinical practice due to the risk of Scleroderma Renal Crisis. Always monitor blood pressure closely. If SRC occurs, ACE inhibitors (Captopril) are the life-saving treatment of choice.

Answer 1

The Correct Option is A

Concept:
The patient is a 42-year-old female with diffuse cutaneous Systemic Sclerosis (SSc). She presents with severe respiratory symptoms (shortness of breath and cough).
Investigations reveal severe, dual pulmonary complications: Interstitial Lung Disease (ILD) indicated by a restricted FVC (50%), and Pulmonary Hypertension (PH) indicated by a disproportionately lower DLCO (30%), RV enlargement, and dilated pulmonary artery.
The goal is to identify the most appropriate immediate medical intervention.
Explanation:

• Systemic Sclerosis is heavily associated with two major pulmonary causes of mortality: SSc-associated Interstitial Lung Disease (SSc-ILD) and Pulmonary Arterial Hypertension (PAH).

• This patient is experiencing a severe, symptomatic acute presentation with drastically reduced pulmonary function tests (FVC 50%, DLCO 30%).

• In the setting of an acute, highly active, and symptomatic inflammatory flare of connective-tissue-disease-associated interstitial lung disease (often suspected when symptoms rapidly worsen), systemic corticosteroids are utilized as a bridging therapy to rapidly suppress the acute inflammatory cascade (alveolitis).

• Corticosteroids provide a much faster onset of anti-inflammatory action compared to steroid-sparing immunosuppressants like Cyclophosphamide (Option B) or Mycophenolate, which take weeks to months to reach peak efficacy.

• Caution is required: in diffuse systemic sclerosis, high doses of corticosteroids ($>$ 15-20 mg/day of prednisone) carry a known risk of precipitating Scleroderma Renal Crisis (SRC). Thus, if steroids are used for an acute pulmonary flare, the patient's blood pressure and renal function must be monitored vigilantly.

• Option (D), Bosentan, is an endothelin receptor antagonist used specifically for Pulmonary Arterial Hypertension. While she has signs of PH, her PH is likely WHO Group 3 (secondary to severe ILD and hypoxia) rather than isolated Group 1 PAH. Treating the underlying inflammatory ILD takes initial precedence.

• Option (C), Lung transplant, is a final resort for end-stage fibrotic disease failing all medical therapy, not the next immediate medical step.
Final answer:
Hence, initiating systemic steroids is the immediate next step to rapidly manage the acute inflammatory component of her severe lung disease.